Douglas Jacobstein

Osiris Therapeutics, Inc. engages in the research, development, manufacture, and commercialization of regenerative medicine products. Its biosurgery business focuses on using unique tissue preservation technologies to develop viable human tissue products designed to improve wound closure and surgical outcomes for patients and physicians over standard of care alone. The company was founded by Peter A. Friedli and James S. Burns on December 23, 1992 and is headquartered in Columbia, MD.

Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical Company focused on the discovery, development and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland. Genetics, environment, aberrant immune response, and barrier dysfunction are all required for autoimmunity. Alba's technology platform is based on modifying disease state epithelial permeability using compounds which impact the regulation of tight junctions in cell barriers throughout the body with potential applications in celiac disease, Crohn's disease, asthma/COPD and acute lung injury. As a development stage company Alba maximizes value creation by leveraging its human capital, partnerships and technology. Since the Company's formation in 2004, the company has entered human clinical trials with its lead product, received Fast Track designation from the FDA (in Celiac Disease), successfully completed three Phase I clinical trials and completed its first Phase II study. Along with $30m raised in its Series A financing, equity and non-equity capital, such as SBIR and ATP grants and venture debt, are being used to develop products, enhance its powerful IP position and build the Company's infrastructure and core competencies

Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn’s disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.